1. "Melanoma and Immunotherapeutics Service"
Formats
  1. Journal Article (954)
  2. Meeting Abstract (771)
  3. Book Section (42)
  4. Editorial (32)
  5. Review (26)
  6. Research Letter (15)
  7. Guidelines (6)
  8. Correspondence (5)
  9. Conference Paper (4)
  10. Miscellaneous (3)
  11. Book Whole (2)
Groups
  1. Department of Medicine (1860)
  2. Melanoma and Immunotherapeutics Service (1860)
  3. Solid Tumor Oncology Division (1860)
  4. GSK Faculty (1050)
  5. Melanoma Disease Management Team (782)
  6. Hematologic Malignancies, Division of (507)

More Groups

People
  1. Jedd Wolchok (905)
  2. Taha Merghoub (364)
  3. Michael Postow (361)
  4. Paul Chapman (326)
  5. Alexander Shoushtari (244)
  6. Margaret Callahan (197)

More People

Years
  1. 2025 (22)
  2. 2024 (46)
  3. 2023 (66)
  4. 2022 (125)
  5. 2021 (112)
  6. 2020 (122)

More Years

Publications
  1. Journal of Clinical Oncology (330)
  2. Journal for ImmunoTherapy of Cancer (131)
  3. Cancer Research (106)
  4. Clinical Cancer Research (90)
  5. Annals of Oncology (77)
  6. Proceedings of the American Association for Cancer Research Annual Meeting (43)

More Publications

Publishers
  1. American Society of Clinical Oncology (342)
  2. American Association for Cancer Research (274)
  3. Biomed Central Ltd (148)
  4. Elsevier Inc. (144)
  5. Oxford University Press (109)
  6. Nature Publishing Group (88)

More Publishers

Results (1860)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma
    Journal Article

    Skoulidis, F.; Goldberg, M. E.; Greenawalt, D. M.; Hellmann, M. D.; Awad, M. M.; Gainor, J. F.; Schrock, A. B.; Hartmaier, R. J.; Trabucco, S. E.; Gay, L.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save
  • Primary and metastatic melanoma with NTRK fusions
    Journal Article

    Lezcano, C.; Shoushtari, A. N.; Ariyan, C.; Hollmann, T. J.; Busam, K. J.
    American Journal of Surgical Pathology (2018)

    Fulltext@MSK | Save
  • Combination controversies: Checkpoint inhibition alone or in combination for the treatment of melanoma?
    Journal Article

    Warner, A. B.; Postow, M. A.
    Oncology (Norwalk) (2018)

    Fulltext@MSK | Save
  • Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers
    Journal Article

    Teo, M. Y.; Seier, K.; Ostrovnaya, I.; Regazzi, A. M.; Kania, B. E.; Moran, M. M.; Cipolla, C. K.; Bluth, M. J.; Chaim, J.; Al-Ahmadie, H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
    Journal Article

    Oseledchyk, A.; Ricca, J. M.; Gigoux, M.; Ko, B.; Redelman-Sidi, G.; Walther, T.; Liu, C.; Iyer, G.; Merghoub, T.; Wolchok, J. D.; more...
    Oncotarget (2018)

    Fulltext@MSK | Save
  • Neoadjuvant PD-1 blockade in resectable lung cancer
    Journal Article

    Forde, P. M.; Chaft, J. E.; Smith, K. N.; Anagnostou, V.; Cottrell, T. R.; Hellmann, M. D.; Zahurak, M.; Yang, S. C.; Jones, D. R.; Broderick, S.; more...
    New England Journal of Medicine (2018)

    Fulltext@MSK | Save
  • Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline
    Journal Article

    Brahmer, J. R.; Lacchetti, C.; Schneider, B. J.; Atkins, M. B.; Brassil, K. J.; Caterino, J. M.; Chau, I.; Ernstoff, M. S.; Gardner, J. M.; Ginex, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma
    Journal Article

    Robert, C.; Ribas, A.; Hamid, O.; Daud, A.; Wolchok, J. D.; Joshua, A. M.; Hwu, W. J.; Weber, J. S.; Gangadhar, T. C.; Joseph, R. W.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Introducing a new series: Immunotherapy facts and hopes
    Journal Article

    Melero, I.; Sznol, M.; Tessmer, M. S.; Whiteside, T. L.; Wolchok, J. D.
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse? [interview]
    Journal Article

    Postow, M. A.
    Clinical Advances in Hematology & Oncology (2018)

    Fulltext@MSK | Save